Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

Returns on capital

Coherus Oncology, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-279.1%

avg 200.0%

ROIC

-151.8%

avg -103.3%

ROA

-65.9%

avg -63.3%

Analysis

ROA is currently the strongest return metric at -65.9% versus its period average of -63.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Dennis Lanfear

Chairman, President & Chief Executive OfficerUSD 1.91M71——

Sameer Goregaoker

Chief Commercial OfficerUSD 854.06K———

Bryan J. McMichael

Chief Financial OfficerUSD 788.89K470<0.01%

Arvind Sood

Chief Strategy & Corporate Affairs Officer————

Michael Chen

Senior Vice President of Commercial Analytics & Trade————

Carrie Graham

Vice President of Investor Relations & Advocacy————

Rebecca Sunshine

Chief Human Resources Officer—63——

Andy Rittenberg

Chief Legal Officer————

Rosh Dias MRCP

Chief Medical Officer—58——

Theresa Lavallee

Chief Development Officer & Chairman of Scientific Advisory Board—60——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 29, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-41.5%
+50.3% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at -41.5% over three years. Forward estimates point to Revenue at +50.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Coherus Oncology, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CHRS's management, answered from reported figures.

Who manages CHRS?

Coherus Oncology, Inc. (CHRS) lists 10 active executives. The top listed executive is Arvind Sood, Chief Strategy & Corporate Affairs Officer.

Are CHRS insiders buying or selling?

Recent insider activity shows net selling of $23.21M.